Cargando…

4063 Glycemic control in a weight management-focused group medical visits (WM/GMV) intervention: examining the moderating effects of body mass index (BMI)

OBJECTIVES/GOALS: The impact of baseline BMI on glycemic response to group medical visits (GMV) and weight management (WM)-based interventions is unclear. Our objective is to determine how baseline BMI class impacts patient responses to GMV and interventions that combine WM/GMV. METHODS/STUDY POPULA...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobe, Elizabeth, Coffman, Cynthia J., Jeffreys, Amy S., Yancy, William S., Zervakis, Jennifer, Edelman, David E., Crowley, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823094/
http://dx.doi.org/10.1017/cts.2020.130
_version_ 1784646737850269696
author Kobe, Elizabeth
Coffman, Cynthia J.
Jeffreys, Amy S.
Yancy, William S.
Zervakis, Jennifer
Edelman, David E.
Crowley, Matthew J.
author_facet Kobe, Elizabeth
Coffman, Cynthia J.
Jeffreys, Amy S.
Yancy, William S.
Zervakis, Jennifer
Edelman, David E.
Crowley, Matthew J.
author_sort Kobe, Elizabeth
collection PubMed
description OBJECTIVES/GOALS: The impact of baseline BMI on glycemic response to group medical visits (GMV) and weight management (WM)-based interventions is unclear. Our objective is to determine how baseline BMI class impacts patient responses to GMV and interventions that combine WM/GMV. METHODS/STUDY POPULATION: We will perform a secondary analysis of Jump Start, a randomized, controlled trial that compared the effectiveness of a GMV-based low carbohydrate diet-focused WM program (WM/GMV) to traditional GMV-based medication management (GMV) on diabetes control. The primary and secondary outcomes will be change in hemoglobin A1c (HbA1c) and weight at 48 months, respectively. Study participants will be stratified into BMI categories defined by BMI 27-29.9kg/m(2), 30.0-34.9kg/m(2), 35.0-39.9kg/m(2), and ≥40.0kg/m(2). Hierarchical mixed models will be used to examine the differential impact of the WM/GMV intervention compared to GMV on changes in outcomes by BMI class category. RESULTS/ANTICIPATED RESULTS: Jump Start enrolled 263 overweight Veterans (BMI ≥ 27kg/m(2)) with type 2 diabetes. At baseline, mean BMI was 35.3 and mean HbA1c was 9.1. 14.5% were overweight (BMI 27–29.9) and 84.5% were obese (BMI ≥ 30). The proposed analyses are ongoing. We anticipate that patients in the higher BMI obesity classes will demonstrate greater reductions in HbA1c and weight with the WM/GMV intervention relative to traditional GMV. DISCUSSION/SIGNIFICANCE OF IMPACT: This work will advance the understanding of the relationship between BMI and glycemic response to targeted interventions, and may ultimately provide guidance for interventions for type 2 diabetes.
format Online
Article
Text
id pubmed-8823094
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-88230942022-02-18 4063 Glycemic control in a weight management-focused group medical visits (WM/GMV) intervention: examining the moderating effects of body mass index (BMI) Kobe, Elizabeth Coffman, Cynthia J. Jeffreys, Amy S. Yancy, William S. Zervakis, Jennifer Edelman, David E. Crowley, Matthew J. J Clin Transl Sci Clinical Epidemiology/Clinical Trial OBJECTIVES/GOALS: The impact of baseline BMI on glycemic response to group medical visits (GMV) and weight management (WM)-based interventions is unclear. Our objective is to determine how baseline BMI class impacts patient responses to GMV and interventions that combine WM/GMV. METHODS/STUDY POPULATION: We will perform a secondary analysis of Jump Start, a randomized, controlled trial that compared the effectiveness of a GMV-based low carbohydrate diet-focused WM program (WM/GMV) to traditional GMV-based medication management (GMV) on diabetes control. The primary and secondary outcomes will be change in hemoglobin A1c (HbA1c) and weight at 48 months, respectively. Study participants will be stratified into BMI categories defined by BMI 27-29.9kg/m(2), 30.0-34.9kg/m(2), 35.0-39.9kg/m(2), and ≥40.0kg/m(2). Hierarchical mixed models will be used to examine the differential impact of the WM/GMV intervention compared to GMV on changes in outcomes by BMI class category. RESULTS/ANTICIPATED RESULTS: Jump Start enrolled 263 overweight Veterans (BMI ≥ 27kg/m(2)) with type 2 diabetes. At baseline, mean BMI was 35.3 and mean HbA1c was 9.1. 14.5% were overweight (BMI 27–29.9) and 84.5% were obese (BMI ≥ 30). The proposed analyses are ongoing. We anticipate that patients in the higher BMI obesity classes will demonstrate greater reductions in HbA1c and weight with the WM/GMV intervention relative to traditional GMV. DISCUSSION/SIGNIFICANCE OF IMPACT: This work will advance the understanding of the relationship between BMI and glycemic response to targeted interventions, and may ultimately provide guidance for interventions for type 2 diabetes. Cambridge University Press 2020-07-29 /pmc/articles/PMC8823094/ http://dx.doi.org/10.1017/cts.2020.130 Text en © The Association for Clinical and Translational Science 2020 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Epidemiology/Clinical Trial
Kobe, Elizabeth
Coffman, Cynthia J.
Jeffreys, Amy S.
Yancy, William S.
Zervakis, Jennifer
Edelman, David E.
Crowley, Matthew J.
4063 Glycemic control in a weight management-focused group medical visits (WM/GMV) intervention: examining the moderating effects of body mass index (BMI)
title 4063 Glycemic control in a weight management-focused group medical visits (WM/GMV) intervention: examining the moderating effects of body mass index (BMI)
title_full 4063 Glycemic control in a weight management-focused group medical visits (WM/GMV) intervention: examining the moderating effects of body mass index (BMI)
title_fullStr 4063 Glycemic control in a weight management-focused group medical visits (WM/GMV) intervention: examining the moderating effects of body mass index (BMI)
title_full_unstemmed 4063 Glycemic control in a weight management-focused group medical visits (WM/GMV) intervention: examining the moderating effects of body mass index (BMI)
title_short 4063 Glycemic control in a weight management-focused group medical visits (WM/GMV) intervention: examining the moderating effects of body mass index (BMI)
title_sort 4063 glycemic control in a weight management-focused group medical visits (wm/gmv) intervention: examining the moderating effects of body mass index (bmi)
topic Clinical Epidemiology/Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823094/
http://dx.doi.org/10.1017/cts.2020.130
work_keys_str_mv AT kobeelizabeth 4063glycemiccontrolinaweightmanagementfocusedgroupmedicalvisitswmgmvinterventionexaminingthemoderatingeffectsofbodymassindexbmi
AT coffmancynthiaj 4063glycemiccontrolinaweightmanagementfocusedgroupmedicalvisitswmgmvinterventionexaminingthemoderatingeffectsofbodymassindexbmi
AT jeffreysamys 4063glycemiccontrolinaweightmanagementfocusedgroupmedicalvisitswmgmvinterventionexaminingthemoderatingeffectsofbodymassindexbmi
AT yancywilliams 4063glycemiccontrolinaweightmanagementfocusedgroupmedicalvisitswmgmvinterventionexaminingthemoderatingeffectsofbodymassindexbmi
AT zervakisjennifer 4063glycemiccontrolinaweightmanagementfocusedgroupmedicalvisitswmgmvinterventionexaminingthemoderatingeffectsofbodymassindexbmi
AT edelmandavide 4063glycemiccontrolinaweightmanagementfocusedgroupmedicalvisitswmgmvinterventionexaminingthemoderatingeffectsofbodymassindexbmi
AT crowleymatthewj 4063glycemiccontrolinaweightmanagementfocusedgroupmedicalvisitswmgmvinterventionexaminingthemoderatingeffectsofbodymassindexbmi